ArriVent BioPharma (AVBP) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
ArriVent BioPharma is the larger company by market cap ($832.8 million vs $731.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | AVBP | DSGN |
|---|---|---|
| Share price | $16.89 | $11.69 |
| Market cap | $832.81M | $731.58M |
| 1-day change | +11.93% | -2.34% |
| YTD return | — | +24.63% |
| 1-year return | — | +80.12% |
| 5-year return | — | -17.96% |
| EPS (TTM) | $-3.62 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $17.25 |
| 52-week low | $11.36 | $5.28 |
| Distance from 52-week high | -52.86% | -32.23% |
| Average volume | 827.30K | 614.39K |
| Shares outstanding | 49.31M | 62.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AVBP vs DSGN FAQ
Which is bigger, ArriVent BioPharma or Design Therapeutics?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $832.81M compared with $731.58M for Design Therapeutics (DSGN).
Are ArriVent BioPharma and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.